Idiopathic pulmonary fibrosis: treatment update.

Authors
O'Connell, Oisin J
Kennedy, Marcus P
Henry, Michael T
Affiliation
Department of Respiratory Medicine, Cork University Hospital, Wilton, Cork, Ireland.
Issue Date
2011-11
MeSH
Anti-Inflammatory Agents
Anticoagulants
Antioxidants
Clinical Trials as Topic
Combined Modality Therapy
Disease Progression
Humans
Idiopathic Pulmonary Fibrosis
Immunosuppressive Agents
Lung Transplantation
Medication Therapy Management
Outcome Assessment (Health Care)
Oxygen Inhalation Therapy
Palliative Care
Receptors, Endothelin
Tumor Necrosis Factor-alpha

Metadata
Show full item record
Citation
Idiopathic pulmonary fibrosis: treatment update. 2011, 28 (11):986-99 Adv Ther
Journal
Advances in therapy
URI
http://hdl.handle.net/10147/218049
DOI
10.1007/s12325-011-0066-5
PubMed ID
21975927
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.
Language
en
ISSN
1865-8652
Ethical Approval
N/A
Collections